Loading...

We've got a brand new version of Simply Wall St! Try it out

MYCELX Technologies

AIM:MYX
Snowflake Description

Very undervalued with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MYX
AIM
£10M
Market Cap
  1. Home
  2. GB
  3. Commercial Services
Company description

MYCELX Technologies Corporation, a clean water technology company, provides novel water treatment solutions to the oil and gas, power, marine, and heavy manufacturing sectors in the Middle East, the United States, and internationally. The last earnings update was 61 days ago. More info.


Add to Portfolio Compare Print
  • MYCELX Technologies has significant price volatility in the past 3 months.
MYX Share Price and Events
7 Day Returns
0%
AIM:MYX
0.8%
GB Commercial Services
-0.4%
GB Market
1 Year Returns
-77.2%
AIM:MYX
17.6%
GB Commercial Services
4.5%
GB Market
MYX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MYCELX Technologies (MYX) 0% -21.1% -23.4% -77.2% 50% -76.7%
GB Commercial Services 0.8% 1.4% 5.6% 17.6% 13.7% 10.6%
GB Market -0.4% 1.7% 4.7% 4.5% 6.9% 2.9%
1 Year Return vs Industry and Market
  • MYX underperformed the Commercial Services industry which returned 17.6% over the past year.
  • MYX underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned 4.5% over the past year.
Price Volatility
MYX
Industry
5yr Volatility vs Market

Value

 Is MYCELX Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MYCELX Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MYCELX Technologies.

AIM:MYX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.3%
Perpetual Growth Rate 10-Year GB Government Bond Rate 1.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for AIM:MYX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 1.2%
Equity Risk Premium S&P Global 6%
Commercial Services Unlevered Beta Simply Wall St/ S&P Global 0.66
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.66 (1 + (1- 21%) (22.83%))
0.852
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.85
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.23% + (0.852 * 5.96%)
6.31%

Discounted Cash Flow Calculation for AIM:MYX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MYCELX Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

AIM:MYX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.31%)
2020 0.10 Analyst x1 0.09
2021 2.30 Analyst x1 2.04
2022 4.19 Est @ 82.15% 3.49
2023 6.61 Est @ 57.87% 5.18
2024 9.32 Est @ 40.88% 6.86
2025 12.02 Est @ 28.98% 8.33
2026 14.50 Est @ 20.66% 9.45
2027 16.65 Est @ 14.83% 10.21
2028 18.44 Est @ 10.75% 10.64
2029 19.90 Est @ 7.89% 10.79
Present value of next 10 years cash flows $67.00
AIM:MYX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $19.90 × (1 + 1.23%) ÷ (6.31% – 1.23%)
$396.51
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $396.51 ÷ (1 + 6.31%)10
$215.11
AIM:MYX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $67.00 + $215.11
$282.11
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $282.11 / 19.44
$14.51
AIM:MYX Discount to Share Price
Calculation Result
Exchange Rate USD/GBP
(Reporting currency to currency of AIM:MYX)
0.775
Value per Share
(GBP)
= Value per Share in USD x Exchange Rate (USD/GBP)
= $14.51 x 0.775
£11.25
Value per share (GBP) From above. £11.25
Current discount Discount to share price of £0.53
= -1 x (£0.53 - £11.25) / £11.25
95.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price MYCELX Technologies is available for.
Intrinsic value
>50%
Share price is £0.53 vs Future cash flow value of £11.25
Current Discount Checks
For MYCELX Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • MYCELX Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • MYCELX Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MYCELX Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MYCELX Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:MYX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $0.09
AIM:MYX Share Price ** AIM (2019-11-15) in GBP £0.53
AIM:MYX Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.29 $0.68
United Kingdom of Great Britain and Northern Ireland Commercial Services Industry PE Ratio Median Figure of 24 Publicly-Listed Commercial Services Companies 18.65x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 751 Publicly-Listed Companies 17.16x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MYCELX Technologies.

AIM:MYX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:MYX Share Price ÷ EPS (both in USD)

= 0.68 ÷ 0.09

7.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MYCELX Technologies is good value based on earnings compared to the GB Commercial Services industry average.
  • MYCELX Technologies is good value based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does MYCELX Technologies's expected growth come at a high price?
Raw Data
AIM:MYX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 7.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
54.9%per year
United Kingdom of Great Britain and Northern Ireland Commercial Services Industry PEG Ratio Median Figure of 19 Publicly-Listed Commercial Services Companies 1.21x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 558 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

AIM:MYX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 7.94x ÷ 54.9%

0.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MYCELX Technologies is good value based on expected growth next year.
Price based on value of assets
What value do investors place on MYCELX Technologies's assets?
Raw Data
AIM:MYX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $1.17
AIM:MYX Share Price * AIM (2019-11-15) in GBP £0.53
AIM:MYX Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.29 $0.68
United Kingdom of Great Britain and Northern Ireland Commercial Services Industry PB Ratio Median Figure of 31 Publicly-Listed Commercial Services Companies 1.79x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,305 Publicly-Listed Companies 1.52x
AIM:MYX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:MYX Share Price ÷ Book Value per Share (both in USD)

= 0.68 ÷ 1.17

0.58x

* Primary Listing of MYCELX Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MYCELX Technologies is good value based on assets compared to the GB Commercial Services industry average.
X
Value checks
We assess MYCELX Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. MYCELX Technologies has a total score of 6/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MYCELX Technologies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
54.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MYCELX Technologies expected to grow at an attractive rate?
  • MYCELX Technologies's earnings growth is expected to exceed the low risk savings rate of 1.2%.
Growth vs Market Checks
  • MYCELX Technologies's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • MYCELX Technologies's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:MYX Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:MYX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 54.9%
AIM:MYX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 19%
United Kingdom of Great Britain and Northern Ireland Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 15.9%
United Kingdom of Great Britain and Northern Ireland Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 4.7%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 12.6%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:MYX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:MYX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 34 5 4 1
2020-12-31 30 3 3 1
2019-12-31 20 4 1 1
2019-11-16
AIM:MYX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 24 -2 2
2019-03-31 25 -1 2
2018-12-31 27 0 3
2018-09-30 23 1 2
2018-06-30 20 1 1
2018-03-31 17 1 0
2017-12-31 14 0 -1
2017-09-30 12 0 -2
2017-06-30 10 -1 -2
2017-03-31 9 0 -3
2016-12-31 8 0 -3
2016-09-30 8 0 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MYCELX Technologies's earnings are expected to grow significantly at over 20% yearly.
  • MYCELX Technologies's revenue is expected to grow by 19% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:MYX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from MYCELX Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:MYX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.21 0.21 0.21 1.00
2020-12-31 0.17 0.17 0.17 1.00
2019-12-31 0.02 0.02 0.02 1.00
2019-11-16
AIM:MYX Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 0.09
2019-03-31 0.12
2018-12-31 0.16
2018-09-30 0.11
2018-06-30 0.05
2018-03-31 -0.01
2017-12-31 -0.06
2017-09-30 -0.09
2017-06-30 -0.12
2017-03-31 -0.15
2016-12-31 -0.17
2016-09-30 -0.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • MYCELX Technologies is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess MYCELX Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MYCELX Technologies has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MYCELX Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MYCELX Technologies's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MYCELX Technologies has delivered over 20% year on year earnings growth in the past 5 years.
  • MYCELX Technologies's 1-year earnings growth exceeds its 5-year average (83.1% vs 51.1%)
  • MYCELX Technologies's earnings growth has exceeded the GB Commercial Services industry average in the past year (83.1% vs 14.9%).
Earnings and Revenue History
MYCELX Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MYCELX Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:MYX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 23.86 1.62 9.60 0.05
2019-03-31 25.41 2.34 9.43 0.02
2018-12-31 26.95 3.07 9.26
2018-09-30 23.49 1.98 8.89
2018-06-30 20.03 0.88 8.51
2018-03-31 16.89 -0.14 8.14
2017-12-31 13.75 -1.16 7.77
2017-09-30 11.80 -1.72 7.17
2017-06-30 9.86 -2.28 6.57
2017-03-31 8.89 -2.78 6.58
2016-12-31 7.92 -3.28 6.59
2016-09-30 8.39 -3.43 7.00 0.02
2016-06-30 8.85 -3.59 7.41 0.03
2016-03-31 11.22 -3.62 8.50 0.10
2015-12-31 13.59 -3.65 9.59 0.17
2015-09-30 14.19 -4.40 10.25 0.30
2015-06-30 14.79 -5.14 10.91 0.43
2015-03-31 14.19 -5.53 11.19 0.44
2014-12-31 13.58 -5.92 11.47 0.44
2014-09-30 16.51 -3.88 11.41 0.44
2014-06-30 19.44 -1.83 11.35 0.43
2014-03-31 20.41 -0.63 10.61 0.46
2013-12-31 21.38 0.57 9.86 0.48
2013-09-30 19.00 0.10 9.08 0.59
2013-06-30 16.63 -0.37 8.29 0.69
2013-03-31 14.46 -1.17 7.68 0.78
2012-12-31 12.30 -1.98 7.07 0.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • MYCELX Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • MYCELX Technologies used its assets more efficiently than the GB Commercial Services industry average last year based on Return on Assets.
  • MYCELX Technologies has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess MYCELX Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MYCELX Technologies has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MYCELX Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MYCELX Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MYCELX Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MYCELX Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MYCELX Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 9.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MYCELX Technologies Company Filings, last reported 4 months ago.

AIM:MYX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 22.83 1.79 3.52
2019-03-31 22.83 1.79 3.52
2018-12-31 20.97 1.83 4.87
2018-09-30 20.97 1.83 4.87
2018-06-30 19.40 1.88 4.97
2018-03-31 19.40 1.88 4.97
2017-12-31 17.82 1.92 5.17
2017-09-30 17.82 1.92 5.17
2017-06-30 18.37 1.96 4.17
2017-03-31 18.37 1.96 4.17
2016-12-31 18.84 2.01 5.14
2016-09-30 18.84 2.01 5.14
2016-06-30 20.55 2.05 5.25
2016-03-31 20.55 2.05 5.25
2015-12-31 22.00 2.08 5.30
2015-09-30 22.00 2.08 5.30
2015-06-30 24.00 3.88 7.24
2015-03-31 24.00 3.88 7.24
2014-12-31 25.02 5.59 11.29
2014-09-30 25.02 5.59 11.29
2014-06-30 16.83 4.54 1.34
2014-03-31 16.83 4.54 1.34
2013-12-31 19.05 5.06 3.66
2013-09-30 19.05 5.06 3.66
2013-06-30 17.54 2.28 2.85
2013-03-31 17.54 2.28 2.85
2012-12-31 16.45 0.00 9.06
  • MYCELX Technologies's level of debt (7.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (26.9% vs 7.8% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 33.4x coverage).
X
Financial health checks
We assess MYCELX Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MYCELX Technologies has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MYCELX Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MYCELX Technologies dividends.
If you bought £2,000 of MYCELX Technologies shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MYCELX Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MYCELX Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:MYX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 680 Stocks 4.5%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:MYX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-11-16

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MYCELX Technologies has not reported any payouts.
  • Unable to verify if MYCELX Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MYCELX Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MYCELX Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MYCELX Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MYCELX Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MYCELX Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MYCELX Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Connie Mixon
COMPENSATION $538,084
AGE 64
TENURE AS CEO 15.6 years
CEO Bio

Ms. Connie Mixon serves as the Chief Executive Officer of MyCelx Technologies Corporation. Ms. Mixon joined MyCelx Technologies in 2004 and was responsible for rapidly developing the commercial and financial infrastructure to provide MyCelx products to a global customer base. Prior to MyCelx in 2004, Ms. Mixon served as a Director for Global Markets at Deutsche Bank. Her career with investment banks included pioneering Deutsche Banks institutional presence in the southern region of the US. Before her tenure at Deutsche Bank, Ms. Mixon served as Vice President at Donaldson, Lufkin & Jenrette, part of the Credit Suisse group of companies. She serves as Director of MyCelx Technologies Corporation. Ms. Mixon holds an MBA from Emory University and a BA in politics from Wake Forest University.

CEO Compensation
  • Connie's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Connie's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the MYCELX Technologies management team in years:

9.6
Average Tenure
64
Average Age
  • The average tenure for the MYCELX Technologies management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Connie Mixon

TITLE
CEO & Executive Director
COMPENSATION
$538K
AGE
64
TENURE
15.6 yrs

Hal Alper

TITLE
Co-Founder
COMPENSATION
$270K
AGE
62

John Mansfield

TITLE
Co-Founder & Chairman Emeritus
AGE
87
TENURE
25.8 yrs

Kim Slayton

TITLE
CFO & Secretary
TENURE
3.7 yrs

Trent Weber

TITLE
Chief Operations Officer
TENURE
0.6 yrs

Andy Narayanan

TITLE
Director of Global Technical Solutions & Key Accounts
Board of Directors Tenure

Average tenure and age of the MYCELX Technologies board of directors in years:

0.8
Average Tenure
66
Average Age
  • The average tenure for the MYCELX Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Tim Eggar

TITLE
Non-Executive Chairman
COMPENSATION
$57K
AGE
68
TENURE
8.4 yrs

Connie Mixon

TITLE
CEO & Executive Director
COMPENSATION
$538K
AGE
64

Hal Alper

TITLE
Co-Founder
COMPENSATION
$270K
AGE
62

John Mansfield

TITLE
Co-Founder & Chairman Emeritus
AGE
87

André Schnabl

TITLE
Senior Independent Director
TENURE
0.8 yrs

Tom Lamb

TITLE
Non-Executive Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
16. Aug 19 Buy Connie Mixon Individual 16. Aug 19 16. Aug 19 450,000 £0.55 £247,500
16. Aug 19 Buy Timothy John Eggar Individual 16. Aug 19 16. Aug 19 8,182 £0.55 £4,500
X
Management checks
We assess MYCELX Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MYCELX Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is MYCELX Technologies's (LON:MYX) Share Price Gain Of 128% Well Earned?

MYCELX Technologies Corporation (LON:MYX) shareholders might understandably be very concerned that the share price has dropped 67% in the last quarter. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. … However, it could simply be that the share price has been impacted by broader market jitters.

Simply Wall St -

A Close Look At MYCELX Technologies Corporation’s (LON:MYX) 19% ROCE

The formula for calculating the return on capital employed is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for MYCELX Technologies: 0.19 = US$4.4m ÷ (US$28m - US$5.2m) (Based on the trailing twelve months to December 2018.) Therefore, MYCELX Technologies has an ROCE of 19%. … What Are Current Liabilities, And How Do They Affect MYCELX Technologies's ROCE? … Due to the way ROCE is calculated, a high level of current liabilities makes a company look as though it has less capital employed, and thus can (sometimes unfairly) boost the ROCE.

Simply Wall St -

Is MYCELX Technologies Corporation (LON:MYX) Excessively Paying Its CEO?

Check out our latest analysis for MYCELX Technologies How Does Connie Mixon's Compensation Compare With Similar Sized Companies? … It would therefore appear that MYCELX Technologies Corporation pays Connie Mixon more than the median CEO remuneration at companies of a similar size, in the same market. … We compared total CEO remuneration at MYCELX Technologies Corporation with the amount paid at companies with a similar market capitalization.

Simply Wall St -

Is MYCELX Technologies Corporation's (LON:MYX) Stock Available For A Good Price After Accounting For Growth?

MYCELX Technologies Corporation (LON:MYX) is considered a high-growth stock, but its last closing price of £1.125 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. … But, to properly examine the value of a high-growth stock such as MYCELX Technologies, we must reflect its earnings growth into the valuation. … A PE ratio of 8.74x and expected year-on-year earnings growth of 22% give MYCELX Technologies an extremely low PEG ratio of 0.39x.

Simply Wall St -

How Important Was Sentiment In Driving MYCELX Technologies's Fantastic 1125% Share Price Gain?

For example, the MYCELX Technologies Corporation (LON:MYX) share price is up a whopping 1125% in the last three years, a handsome return for long term holders. … And in the last month, the share price has gained -7.5%. … One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Simply Wall St -

Is MYCELX Technologies Corporation's (LON:MYX) ROE Of 4.6% Concerning?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … One way to conceptualize this, is that for each £1 of shareholders' equity it has, the company made £0.046 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

How Financially Strong Is MYCELX Technologies Corporation (LON:MYX)?

Investors are always looking for growth in small-cap stocks like MYCELX Technologies Corporation (LON:MYX), with a market cap of US$16.89m. … However, an important fact which most ignore is: how financially healthy is the business? … the current state of its operations and pathway to profitability.

Simply Wall St -

When Can We Expect A Profit From MYCELX Technologies Corporation (LON:MYX)?

MYCELX Technologies Corporation, a clean water technology company, provides novel water treatment solutions to the oil and gas, power, marine, and heavy manufacturing sectors in the Middle East, the United States, and internationally. … In this article, I will touch on the expectations for MYX’s growth and when analysts expect the company to become profitable … Check out our latest analysis for MYCELX Technologies

Simply Wall St -

Should You Buy MYCELX Technologies Corporation (LON:MYX) Now?

As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value? … Today I will analyse the most recent data on MYCELX Technologies’s outlook and valuation to see if the opportunity still exists? … According to my valuation model, the stock is currently overvalued by about 54.52%, trading at UK£1.25 compared to my

Simply Wall St -

Flavor Of The Month: MYCELX Technologies And More

GYM’s projected future profit growth is a robust 29.13%, with an underlying 49.46% growth from its revenues expected over the upcoming years. … MBH’s projected future profit growth is a robust 38.78%, with an underlying triple-digit growth from its cash flow from operations expected over the upcoming years. … AIM:MBH Future Profit May 30th 18 For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.

Simply Wall St -

Company Info

Description

MYCELX Technologies Corporation, a clean water technology company, provides novel water treatment solutions to the oil and gas, power, marine, and heavy manufacturing sectors in the Middle East, the United States, and internationally. The company offers oil removal solutions for upstream produced water to oil companies; and hydrocarbons removal services from downstream process wastewater used in petrochemical facilities and refineries. It also sells or leases its equipment; and sells patented consumable filtration media. The company was incorporated in 1994 is headquartered in Duluth, Georgia.

Details
Name: MYCELX Technologies Corporation
MYX
Exchange: AIM
Founded: 1994
£10,207,968
19,443,750
Website: http://www.mycelx.com
Address: MYCELX Technologies Corporation
2420 Meadowbrook Parkway,
Duluth,
Georgia, 30096,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM MYX Common Stock London Stock Exchange AIM Market GB GBP 10. Oct 2012
AIM MYXR COM SHS USD0.025 (REG S) London Stock Exchange AIM Market GB GBP 13. Mar 2019
DB MYX1 COM SHS USD0.025 (REG S) Deutsche Boerse AG DE EUR 13. Mar 2019
Number of employees
Current staff
Staff numbers
0
MYCELX Technologies employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/16 21:42
End of day share price update: 2019/11/15 00:00
Last estimates confirmation: 2019/06/14
Last earnings filing: 2019/09/16
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.